Trial Profile
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms TRUST
- Sponsors Novo Nordisk
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 08 Dec 2017 Results assessing long term safety and efficacy presented at the 2017 Congress of the International Diabetes Federation
- 28 Jul 2017 Status changed from active, no longer recruiting to completed.